These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 24997587)

  • 1. A double-blind, randomized controlled trial to compare the effect of biannual peripheral magnetic resonance imaging, radiography and standard of care disease progression monitoring on pharmacotherapeutic escalation in rheumatoid and undifferentiated inflammatory arthritis: study protocol for a randomized controlled trial.
    Tavares R; Beattie KA; Bensen WG; Bobba RS; Cividino AA; Finlay K; Goeree R; Hart LE; Jurriaans E; Larche MJ; Parasu N; Tarride JE; Webber CE; Adachi JD
    Trials; 2014 Jul; 15():268. PubMed ID: 24997587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of a magnetic resonance imaging-guided treat-to-target strategy on disease activity and progression in patients with rheumatoid arthritis (the IMAGINE-RA trial): study protocol for a randomized controlled trial.
    Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg BJ; Boesen M; Hetland ML; Christensen R; Møller J; Krogh NS; Stengaard-Pedersen K; Østergaard M
    Trials; 2015 Apr; 16():178. PubMed ID: 25896862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Magnetic Resonance Imaging vs Conventional Treat-to-Target Strategies on Disease Activity Remission and Radiographic Progression in Rheumatoid Arthritis: The IMAGINE-RA Randomized Clinical Trial.
    Møller-Bisgaard S; Hørslev-Petersen K; Ejbjerg B; Hetland ML; Ørnbjerg LM; Glinatsi D; Møller J; Boesen M; Christensen R; Stengaard-Pedersen K; Madsen OR; Jensen B; Villadsen JA; Hauge EM; Bennett P; Hendricks O; Asmussen K; Kowalski M; Lindegaard H; Nielsen SM; Bliddal H; Krogh NS; Ellingsen T; Nielsen AH; Balding L; Jurik AG; Thomsen HS; Østergaard M
    JAMA; 2019 Feb; 321(5):461-472. PubMed ID: 30721294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The smallest detectable difference and sensitivity to change of magnetic resonance imaging and radiographic scoring of structural joint damage in rheumatoid arthritis finger, wrist, and toe joints: a comparison of the OMERACT rheumatoid arthritis magnetic resonance imaging score applied to different joint combinations and the Sharp/van der Heijde radiographic score.
    Ejbjerg BJ; Vestergaard A; Jacobsen S; Thomsen HS; Østergaard M
    Arthritis Rheum; 2005 Aug; 52(8):2300-6. PubMed ID: 16052593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.
    Dale J; Stirling A; Zhang R; Purves D; Foley J; Sambrook M; Conaghan PG; van der Heijde D; McConnachie A; McInnes IB; Porter D
    Ann Rheum Dis; 2016 Jun; 75(6):1043-50. PubMed ID: 27026689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
    Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
    Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TREAT Early Arthralgia to Reverse or Limit Impending Exacerbation to Rheumatoid arthritis (TREAT EARLIER): a randomized, double-blind, placebo-controlled clinical trial protocol.
    Niemantsverdriet E; Dakkak YJ; Burgers LE; Bonte-Mineur F; Steup-Beekman GM; van der Kooij SM; Boom HD; Allaart CF; de Jong PHP; van der Helm-van Mil AHM
    Trials; 2020 Oct; 21(1):862. PubMed ID: 33076964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
    Ciubotariu E; Gabay C; Finckh A;
    J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative study of the inhibitory effect on bone erosion progression with denosumab treatment and conventional treatment in rheumatoid arthritis patients: study protocol for an open-label randomized controlled trial by HR-pQCT.
    Iwamoto N; Sato S; Sumiyoshi R; Chiba K; Miyamoto N; Arinaga K; Kobayashi M; Yamamoto H; Osaki M; Kawakami A
    Trials; 2019 Aug; 20(1):494. PubMed ID: 31409388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis.
    Besselink NJ; Westgeest AAA; Klaasen R; Gamala M; van Woerkom JM; Tekstra J; Verhoeven MMA; Van Spil WE; Lafeber FPJG; Marijnissen ACA; Van Laar JM; Jacobs JWG
    Trials; 2019 Apr; 20(1):226. PubMed ID: 30999969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast enhanced Gd-DTPA magnetic resonance imaging in the evaluation of rheumatoid arthritis during a clinical trial with DMARDs. A prospective two-year follow-up study on hand joints in 31 patients.
    Jevtic V; Watt I; Rozman B; Kos-Golja M; Praprotnik S; Logar D; Presetnik M; Demsar F; Jarh O; Campion G; Musikic P
    Clin Exp Rheumatol; 1997; 15(2):151-6. PubMed ID: 9196866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining MRI Inflammation Targets When Considering a Rheumatoid Arthritis Treat-to-Target Strategy: Results of a Randomized, Placebo-Controlled Trial.
    Ahmad HA; Baker JF; Østergaard M; Ye J; Emery P; Conaghan PG
    Adv Ther; 2019 Sep; 36(9):2384-2393. PubMed ID: 31278695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy.
    Conaghan PG; Peterfy C; Olech E; Kaine J; Ridley D; Dicarlo J; Friedman J; Devenport J; Troum O
    Ann Rheum Dis; 2014 May; 73(5):810-6. PubMed ID: 24525910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA).
    Hetland ML; Ejbjerg B; Hørslev-Petersen K; Jacobsen S; Vestergaard A; Jurik AG; Stengaard-Pedersen K; Junker P; Lottenburger T; Hansen I; Andersen LS; Tarp U; Skjødt H; Pedersen JK; Majgaard O; Svendsen AJ; Ellingsen T; Lindegaard H; Christensen AF; Vallø J; Torfing T; Narvestad E; Thomsen HS; Ostergaard M;
    Ann Rheum Dis; 2009 Mar; 68(3):384-90. PubMed ID: 18388160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure in longterm treatment is rare in actively treated patients with rheumatoid arthritis, but may be predicted by high health assessment score at baseline and by residual disease activity at 3 and 6 months: the 5-year followup results of the randomized clinical NEO-RACo trial.
    Rantalaiho V; Kautiainen H; Järvenpää S; Korpela M; Malmi T; Hannonen P; Kaipiainen-Seppänen O; Yli-Kerttula T; Möttönen T; Mustila A; Karjalainen A; Paimela L; Uutela T; Leirisalo-Repo M;
    J Rheumatol; 2014 Dec; 41(12):2379-85. PubMed ID: 25274892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of risk stratification to target therapies in patients with recent onset arthritis; design of a prospective randomized multicenter controlled trial.
    Claessen SJ; Hazes JM; Huisman MA; van Zeben D; Luime JJ; Weel AE
    BMC Musculoskelet Disord; 2009 Jun; 10():71. PubMed ID: 19538718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observation of the curative effect of Guizhi-Shaoyao-Zhimu decoction combined with methotrexate in the treatment of early rheumatoid arthritis based on ultrasonic evaluation: study protocol of a randomized, double-blind, controlled clinical trial.
    Shen J; Chen Q; Yang G; He Y
    Trials; 2021 Nov; 22(1):764. PubMed ID: 34732237
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conventional versus ultrasound treat to target: no difference in magnetic resonance imaging inflammation or joint damage over 2 years in early rheumatoid arthritis.
    Sundin U; Aga AB; Skare Ø; Nordberg LB; Uhlig T; Hammer HB; van der Heijde D; Kvien TK; Lillegraven S; Haavardsholm EA;
    Rheumatology (Oxford); 2020 Sep; 59(9):2550-2555. PubMed ID: 31999341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validity of early MRI structural damage end points and potential impact on clinical trial design in rheumatoid arthritis.
    Baker JF; Conaghan PG; Emery P; Baker DG; Østergaard M
    Ann Rheum Dis; 2016 Jun; 75(6):1114-9. PubMed ID: 26091907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis.
    Symmons D; Tricker K; Roberts C; Davies L; Dawes P; Scott DL
    Health Technol Assess; 2005 Sep; 9(34):iii-iv, ix-x, 1-78. PubMed ID: 16153351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.